FDA Panel Recommends Semax for the Compounding List

From symptom to signal

People turn to Semax hoping for sharper focus or steadier mood under stress. The peptide has a long research history in Russia, where a related nasal formulation is licensed, but it has no FDA approval in the United States. In July 2026, an FDA Pharmacy Compounding Advisory Committee panel voted 8 in favor to 5 against recommending Semax for the Section 503A bulks list, a step that could let more compounding pharmacies prepare it, according to FDA meeting materials and NCPA.

A vote is not an approval. FDA briefing materials note human cognition evidence for Semax remains limited, with most mechanism data coming from animal studies of BDNF signaling. HHS still has to finalize any bulks list change, so nothing about Semax's legal status has actually changed yet.

Common questions

Did the FDA approve Semax? No. An advisory panel voted to recommend it for a compounding list. The FDA has not made a final decision.

Is there strong human evidence for Semax and cognition? Not yet. Most supporting data comes from animal studies and older, small human research abroad.

What changes now for people researching Semax? Nothing immediately. The vote is a recommendation, not a rule change.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.